#api
rm(list = ls())
library(tidyverse)
## -- Attaching packages --------------------------------------- tidyverse 1.3.1 --
## v ggplot2 3.3.5 v purrr 0.3.4
## v tibble 3.1.4 v dplyr 1.0.7
## v tidyr 1.1.4 v stringr 1.4.0
## v readr 2.1.1 v forcats 0.5.1
## -- Conflicts ------------------------------------------ tidyverse_conflicts() --
## x dplyr::filter() masks stats::filter()
## x dplyr::lag() masks stats::lag()
library(RJSONIO)
library(httr)
vec_1 <- "Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery."
vec_1 <- gsub(" ", "+",vec_1)
vec_query <- paste0("https://www.ncbi.nlm.nih.gov/research/litsense-api/api/?query=", vec_1, "&rerank=true")
vec_query
## [1] "https://www.ncbi.nlm.nih.gov/research/litsense-api/api/?query=Survival+but+not+brain+metastasis+response+relates+to+lung+cancer+mutation+status+after+radiosurgery.&rerank=true"
res <- GET(vec_query)
#res$content
data <- fromJSON(rawToChar(res$content))
length(data)
## [1] 100
data[[1]]$text
## [1] "Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery."
data[[1]]["text"]
## $text
## [1] "Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery."
lapply(data, function (x) x[c("text")])
## [[1]]
## [[1]]$text
## [1] "Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery."
##
##
## [[2]]
## [[2]]$text
## [1] "Survival of non-small cell lung cancer patients with brain metastases treated with brain RT stratified by EGFR mutation status."
##
##
## [[3]]
## [[3]]$text
## [1] "The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases."
##
##
## [[4]]
## [[4]]$text
## [1] "The number of brain metastases predicts the survival of non-small cell lung cancer patients with EGFR mutation status."
##
##
## [[5]]
## [[5]]$text
## [1] "EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer."
##
##
## [[6]]
## [[6]]$text
## [1] "This single institution retrospective study of patients with brain metastases from lung cancer who received stereotactic radiosurgery assessed whether smoking history is associated with overall survival, local control, rate of new brain metastases (brain metastasis velocity), and likelihood of neurologic death after brain metastases."
##
##
## [[7]]
## [[7]]$text
## [1] "Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the setting of brain metastases treated with radiation?"
##
##
## [[8]]
## [[8]]$text
## [1] "EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases"
##
##
## [[9]]
## [[9]]$text
## [1] "Mutational status of lung cancer patients and survival outcomes for patients with limited brain metastases."
##
##
## [[10]]
## [[10]]$text
## [1] "In non-small cell lung cancer patients with brain metastases, combined Gamma Knife radiosurgery and immunotherapy or targeted therapy showed an increase in overall survival."
##
##
## [[11]]
## [[11]]$text
## [1] "Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study."
##
##
## [[12]]
## [[12]]$text
## [1] "EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases."
##
##
## [[13]]
## [[13]]$text
## [1] "The Effect of Epidermal Growth Factor Receptor Mutation on Intracranial Progression-Free Survival of Non-Small Cell Lung Cancer Patients with Brain Metastasis Underwent Gamma Knife Radiosurgery"
##
##
## [[14]]
## [[14]]$text
## [1] "Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery."
##
##
## [[15]]
## [[15]]$text
## [1] "Epidermal growth factor receptor mutations: association with favorable local tumor control following Gamma Knife radiosurgery in patients with non-small cell lung cancer and brain metastases."
##
##
## [[16]]
## [[16]]$text
## [1] "Purpose: Determine whether EGFR and KRAS mutations carry prognostic significance in non-small cell lung cancer (NSCLC) patients with brain metastases treated with stereotactic radiosurgery."
##
##
## [[17]]
## [[17]]$text
## [1] "In patients with lung adenocarcinoma and brain metastasis, the EGFR mutation status and concurrent administration of EGFR-TKIs were independently associated with the response to whole-brain radiation therapy and better survival."
##
##
## [[18]]
## [[18]]$text
## [1] "Tumor Histology Predicts Patterns of Failure and Survival in Patients With Brain Metastases From Lung Cancer Treated With Gamma Knife Radiosurgery"
##
##
## [[19]]
## [[19]]$text
## [1] "We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status."
##
##
## [[20]]
## [[20]]$text
## [1] "We evaluated the effects of EGFR mutation status on responses and outcomes in non-small cell lung cancer (NSCLC) patients with BM, treated with upfront or salvage stereotactic radiosurgery (SRS)."
##
##
## [[21]]
## [[21]]$text
## [1] "The median survival of brain metastases of lung cancer ranges from 2 months to 8 months based on age, Karnofsky performance status, primary tumour status, volume or number of intracranial lesions and with occurrence of leptomeningeal metastases or EGFR gene mutation."
##
##
## [[22]]
## [[22]]$text
## [1] "Mutation status and postresection survival of patients with non-small cell lung cancer brain metastasis: implications of biomarker-driven therapy."
##
##
## [[23]]
## [[23]]$text
## [1] "Out of radioresistant tumors, the median survival from the time of radiosurgery is shorter for brain metastases from a melanoma than renal cell carcinoma and the recursive partitioning analysis (RPA) class I status and renal cell carcinoma predicts a longer survival."
##
##
## [[24]]
## [[24]]$text
## [1] "We proposed to identify the efficacy of an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) using whole brain radiotherapy (WBRT)/stereotactic radiosurgery (SRS)/surgery in brain metastases from patients with non-small cell lung cancer (NSCLC) and clarify the association between treatment outcome and EGFR gene mutation status."
##
##
## [[25]]
## [[25]]$text
## [1] "Comparative survival in patients with brain metastases from non-small-cell lung cancer treated before and after implementation of radiosurgery."
##
##
## [[26]]
## [[26]]$text
## [1] "Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases."
##
##
## [[27]]
## [[27]]$text
## [1] "We prospectively addressed whether EGFR and KRAS mutations, EML4-ALK, ROS1 and RET rearrangements, or wild-type (WT), affects radiosurgery outcomes and overall survival (OS) in non-small cell lung cancer (NSCLC) patients with brain metastases (BM)."
##
##
## [[28]]
## [[28]]$text
## [1] "Survival in Patients with >=5 Brain Metastases From Non-Small Cell Lung Cancer Treated With Upfront Stereotactic Radiosurgery."
##
##
## [[29]]
## [[29]]$text
## [1] "Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status"
##
##
## [[30]]
## [[30]]$text
## [1] "Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of response to radiosurgery (SRS)."
##
##
## [[31]]
## [[31]]$text
## [1] "BACKGROUND AND PURPOSE: To analyze outcomes of non-small cell lung cancer (NSCLC) patients with brain metastases harboring EGFR or ALK mutations and examine for differences between tyrosine kinase inhibitors (TKIs) alone, radiotherapy (RT) alone (either whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS)), or combined TKIs and RT."
##
##
## [[32]]
## [[32]]$text
## [1] "Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan"
##
##
## [[33]]
## [[33]]$text
## [1] "Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metastases."
##
##
## [[34]]
## [[34]]$text
## [1] "BACKGROUND: This study tested the hypothesis that time of day of treatment with stereotactic radiosurgery (SRS) has an effect on local control (LC) and overall survival (OS) in a large cohort of patients with non-small cell lung cancer (NSCLC) brain metastases."
##
##
## [[35]]
## [[35]]$text
## [1] "A restrospective study of patients with brain metastases from non-small cell lung cancer (NSCLC) is performed to identify patients who benefit from radiosurgery and to determine prognostic factors for survival."
##
##
## [[36]]
## [[36]]$text
## [1] "Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases."
##
##
## [[37]]
## [[37]]$text
## [1] "We compared the survival time between patients with multiple gamma knife radiosurgery (GKRS) and patients with a single GKRS plus whole brain radiation therapy (WBRT), in patients with multiple metachronous brain metastases from lung cancer."
##
##
## [[38]]
## [[38]]$text
## [1] "Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery."
##
##
## [[39]]
## [[39]]$text
## [1] "Local recurrence and survival following stereotactic radiosurgery for brain metastases from small cell lung cancer."
##
##
## [[40]]
## [[40]]$text
## [1] "Overall and disease-free survival greater than 12 years in metastatic non-small cell lung cancer after linear accelerator-based stereotactic radiosurgery for solitary brain metastasis."
##
##
## [[41]]
## [[41]]$text
## [1] "A phase 3 Radiation Therapy Oncology Group (RTOG) study subset analysis demonstrated improved overall survival (OS) with the addition of stereotactic radiosurgery (SRS) to whole brain radiation therapy (WBRT) in non-small cell lung cancer (NSCLC) patients with 1 to 3 brain metastases."
##
##
## [[42]]
## [[42]]$text
## [1] "BACKGROUND: We investigated effects of genetic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma viral oncogene homolog (KRAS) on overall survival (OS) and local control after stereotactic radiosurgery for brain metastases in non-small cell lung cancer (NSCLC)."
##
##
## [[43]]
## [[43]]$text
## [1] "In non-small-cell lung cancer, TKIs have proven efficacy in improvement of progression-free survival, response rate, and quality of life when compared to chemotherapy in patients with an EGFR mutation and are included in the current standard of care for patients with symptomatic brain metastasis together with WBRT."
##
##
## [[44]]
## [[44]]$text
## [1] "The authors suggested that the lack of survival difference may be related to the high proportion (~80%) of tumors harboring EGFR mutation or ALK translocation among patients with brain metastases in their study, as these mutations are known to be associated with favorable response of CNS disease to targeted tyrosine kinase inhibitors and higher response rates to whole brain radiation therapy compared to wildtype lung cancer."
##
##
## [[45]]
## [[45]]$text
## [1] "A review by Patil et al. on treatment of brain metastases shows that WBRT plus stereotactic radiosurgery (SRS) yielded better local tumor control (HR 0.27; 95% CI 0.14 to 0.52) and improved KPS performance status but is not associated with longer survival."
##
##
## [[46]]
## [[46]]$text
## [1] "This study was conducted to determine prognostic factors for tumor response and patient survival after stereotactic radiosurgery (SRS) for brain metastasis."
##
##
## [[47]]
## [[47]]$text
## [1] "[Two cases of lung cancer patients with postoperative brain metastases obtaining long-term survival after gamma knife radiosurgery]."
##
##
## [[48]]
## [[48]]$text
## [1] "CONCLUSIONS: Younger patients with resected stage IIIA non-small cell lung cancer who have isolated metachronous brain metastases and good performance status do best when treated with metastasectomy or stereotactic radiosurgery."
##
##
## [[49]]
## [[49]]$text
## [1] "Patients with newly diagnosed EGFR-mutated lung cancer presenting to a neurosurgeon with a new diagnosis of brain metastases now have a variety of treatment options available, including whole brain radiation therapy, stereotactic radiosurgery, surgical resection, chemotherapy, and targeted therapeutics such as the EGFR TKIs."
##
##
## [[50]]
## [[50]]$text
## [1] "The purpose of this study was to examine the impact of epidermal growth factor receptor (EGFR) mutation status and tyrosine kinase inhibitors (TKIs) on the survival of brain metastases (BM) in patients with surgically resected non-small cell lung cancer (NSCLC)."
##
##
## [[51]]
## [[51]]$text
## [1] "OBJECT: The aim of this study was to evaluate the imaging response of brain metastases after radiosurgery and to correlate the response with tumor type and patient survival."
##
##
## [[52]]
## [[52]]$text
## [1] "We report a case in which advanced lung cancer with mediastinal lymph node metastasis and recurrence of brain metastasis was completely responsive to combination chemotherapy and gamma knife radiosurgery."
##
##
## [[53]]
## [[53]]$text
## [1] "Brain metastases constitute one of the most detrimental life-threatening condition in humans and are associated with poor survival reaching median overall survival times of 10.7 months in renal cell carcinomas or 18 months in non-small cell lung cancer treated with stereotactic radiosurgery."
##
##
## [[54]]
## [[54]]$text
## [1] "To determine the factors related to optimal treatment of brain metastasis from lung cancer by gamma knife radiosurgery, we investigated those influencing survival and local tumor control."
##
##
## [[55]]
## [[55]]$text
## [1] "Multiple Gamma Knife Radiosurgery for Multiple Metachronous Brain Metastases Associated with Lung Cancer : Survival Time"
##
##
## [[56]]
## [[56]]$text
## [1] "Thallium-201 SPECT in advanced non-small cell lung cancer: in relation with chemotherapeutic response, survival, distant metastasis and p53 status."
##
##
## [[57]]
## [[57]]$text
## [1] "We conclude that fractionated radiosurgery improves survival of patients with brain metastases from breast cancer, especially those with small lesions, good functional status and no other metastatic disease."
##
##
## [[58]]
## [[58]]$text
## [1] "Comment on \"Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery\", by Yang WC et al."
##
##
## [[59]]
## [[59]]$text
## [1] "It is likely that patients with ALK+ or EGFR mutation+ lung cancer or breast cancer brain metastases that are hormone or HER2 responsive and who are deemed highly likely to have a response to systemic therapy could have radiosurgical treatment deferred without an impact on quality of life or survival probabilities."
##
##
## [[60]]
## [[60]]$text
## [1] "Studies suggest that stereotactic radiosurgery is preferable to whole-brain radiation therapy and that immune checkpoint inhibitors and therapies targeted to the T790M mutation and ALK can improve outcomes in patients with non-small cell lung cancer and brain metastases."
##
##
## [[61]]
## [[61]]$text
## [1] "Abbreviations: KPS, Karnofsky performance status; WBRT, whole-brain radiotherapy; SRS, stereotactic radiosurgery; BM, brain metastases; MRI, magnetic resonance imaging; NSCLC, non-small cell lung cancer."
##
##
## [[62]]
## [[62]]$text
## [1] "Individualized early death and long-term survival prediction after stereotactic radiosurgery for brain metastases of non-small cell lung cancer: Two externally validated nomograms."
##
##
## [[63]]
## [[63]]$text
## [1] "This finding supports the hypothesis that the EGFR mutation in lung tumors could be related to the EGFR-TKI response even in the presence of brain metastases."
##
##
## [[64]]
## [[64]]$text
## [1] "PURPOSE: To evaluate the efficacy of gamma knife radiosurgery (GKRS) for the treatment of brain metastases from non small cell lung cancer (NSCLC) and find out the prognostic factors for overall survival."
##
##
## [[65]]
## [[65]]$text
## [1] "Female sex, younger age, higher Karnofsky performance status, controlled primary tumor, absence of systemic metastases, asynchronous presentation of brain metastasis, fewer brain metastases, smaller total volume of brain metastases, surgery prior to radiosurgery, and multiple radiosurgical treatments were also associated with improved survival."
##
##
## [[66]]
## [[66]]$text
## [1] "This study was aimed at optimizing the treatment of non-small-cell lung cancer (NSCLC) patients who are candidates for stereotactic radiosurgery (SRS) for brain metastases and harbor activating epithelial growth factor receptor (EGFR) mutations."
##
##
## [[67]]
## [[67]]$text
## [1] "Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung cancer brain metastases to stereotactic radiosurgery."
##
##
## [[68]]
## [[68]]$text
## [1] "[A case of long-term survival of postoperative brain metastasis of small cell lung cancer effectively treated with chemotherapy, whole brain radiotherapy and stereotactic radiosurgery]."
##
##
## [[69]]
## [[69]]$text
## [1] "Both previous cases had also advanced lung adenocarcinoma with brain metastasis, received therapy with combined chemotherapy or with first-line TKI (gefitinib, erlotinib or afatinib), were diagnosed as having tumor positive for T790M mutation during disease progression, and showed dramatic response to osimertinib therapy despite poor performance status."
##
##
## [[70]]
## [[70]]$text
## [1] "Multimodality MRI-based radiomics approach to predict the posttreatment response of lung cancer brain metastases to gamma knife radiosurgery."
##
##
## [[71]]
## [[71]]$text
## [1] "Four investigated lung cancer patients undergoing stereotactic radiosurgery for brain metastases, with one study observing improved local control and survival in patients treated in the morning."
##
##
## [[72]]
## [[72]]$text
## [1] "We report two cases of lung cancer patients with postoperative solitary brain metastases obtaining long-term survival after gamma knife stereotactic radiosurgery."
##
##
## [[73]]
## [[73]]$text
## [1] "However, with the advent of newer systemic cancer therapies, survival is improving; this change mandates a longitudinal quantitative analysis of the radiographic response of brain metastases to radiosurgery."
##
##
## [[74]]
## [[74]]$text
## [1] "Although emerging data from retrospective studies suggest that stereotactic radiosurgery is effective in combination with checkpoint inhibitors in brain metastases from multiple tumor types, and newer molecular agents such as the BRAF inhibitor dabrafenib are associated with higher response rates and better survival (Table 1), prospective studies are required to evaluate whether these new regimens are comparable or superior to WBRT."
##
##
## [[75]]
## [[75]]$text
## [1] "Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-small cell lung cancer brain metastases patients."
##
##
## [[76]]
## [[76]]$text
## [1] "BACKGROUND: The aim of this study was to evaluate local control and survival rates after stereotactic radiosurgery (SRS) plus whole-brain radiotherapy (WBRT) for the treatment of multiple brain metastases from non-small cell lung cancer (NSCLC)."
##
##
## [[77]]
## [[77]]$text
## [1] "[Advanced lung cancer with mediastinal lymph node metastasis and recurrence of brain metastasis completely responsive to combination chemotherapy and gamma knife radiosurgery--a case report]."
##
##
## [[78]]
## [[78]]$text
## [1] "Multivariate analysis showed that the presence of extracranial malignancy, performance status, multiple brain metastases, patient gender and the time from the initial treatment to radiosurgery were independent determinants for survival."
##
##
## [[79]]
## [[79]]$text
## [1] "OBJECTIVES: To develop and validate a multimodality MRI-based radiomics approach to predicting the posttreatment response of lung cancer brain metastases (LCBM) to gamma knife radiosurgery (GKRS)."
##
##
## [[80]]
## [[80]]$text
## [1] "OBJECTIVE: In the era in which more patients with greater numbers of brain metastases (BMs) are being treated with stereotactic radiosurgery (SRS) alone, it is critical to understand how patient, tumor, and treatment factors affect functional status and overall survival (OS)."
##
##
## [[81]]
## [[81]]$text
## [1] "Is survival or brain control different in selected patients with single brain metastasis (excluding radiosensitive histologies such as small cell lung cancer, leukemia, lymphoma, and germ cell tumor) treated with surgery or radiosurgery?"
##
##
## [[82]]
## [[82]]$text
## [1] "METHODS: In this retrospective analysis, outcomes of 50 patients who underwent linear accelerator-based stereotactic radiosurgery boost within 4 to 6 weeks of whole brain irradiation for >=4 brain metastases were assessed in terms of local control, overall survival, primary involved organ, recursive partitioning analysis class and Karnofsky performance status at the time of stereotactic radiosurgery, number of lesions, age, status of the primary cancer (controlled vs uncontrolled), presence of extracranial disease and toxicity."
##
##
## [[83]]
## [[83]]$text
## [1] "Therefore, we analyzed how combined local tumor treatment of brain metastases using robotic radiosurgery applied simultaneously with a systemic immune checkpoint blockade affected the magnetic resonance imaging (MRI)-based response after three and six months, acute treatment-related toxicities, and the development of PsP."
##
##
## [[84]]
## [[84]]$text
## [1] "PATIENTS AND METHODS: Patients with one to three brain metastases of solid tumors (small-cell lung cancer excluded) with stable systemic disease or asymptomatic primary tumors and WHO performance status (PS) of 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to adjuvant WBRT (30 Gy in 10 fractions) or observation (OBS)."
##
##
## [[85]]
## [[85]]$text
## [1] "PURPOSE/OBJECTIVE(S): To compare the performance of five prognostic models [RTOG recursive partitioning analysis (RPA), Score Index for Radiosurgery in Brain Metastases (SIR), Barnholtz-Sloan-Kattan nomogram (BSKN), diagnosis-specific Graded Prognostic Assessment (dsGPA), and Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)] against actual survival in patients with brain metastases treated with SRS +/- WBRT."
##
##
## [[86]]
## [[86]]$text
## [1] "Kaplan-Meier curves of (a) overall survival (OS) in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases (LM); (b) survival duration before LM according to EGFR driver mutations and/or T790M in plasma (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.29-1.37; P = 0.211), Plasma positive and plasma negative; (c) survival duration before LM according to EGFR driver mutations and/or T790M in plasma using first-generation EGFR-tyrosine kinase inhibitors (HR 2.41, 95% CI 0.87-6.70; P = 0.078), Plasma positive and plasma negative; and (d) survival duration after LM diagnosis according to LM disease control status (HR 10.114, 95% CI 0.29-1.37; P = 0.008), Improved/stable and worse."
##
##
## [[87]]
## [[87]]$text
## [1] "OBJECTIVE Following an initial response of brain metastases to Gamma Knife radiosurgery, regrowth of the enhancing lesion as detected on MRI may represent either radiation necrosis (a treatment-related inflammatory change) or recurrent tumor."
##
##
## [[88]]
## [[88]]$text
## [1] "61-year-old African American woman from Louisiana on investigative anti-PD-L1 and PARP-inhibitor therapy for metastatic rectal cancer involving lungs, peritoneum, and brain, seen for follow-up of brain metastases status-post radiosurgery with stable disease."
##
##
## [[89]]
## [[89]]$text
## [1] "To the best of our knowledge this is the first report on patients treated with linear accelerator-based stereotactic radiosurgery alone where an overall survival of more than 12 years was obtained, maintaining good quality of life in three cases of solitary brain metastasis from non-small cell lung cancer."
##
##
## [[90]]
## [[90]]$text
## [1] "The primary lung cancer dataset (GSE3141) contained survival information and KRAS mutation status for all samples of early-stage patients; in contrast, the brain metastases dataset did not contain any survival information with respect to the stage IV patients."
##
##
## [[91]]
## [[91]]$text
## [1] "[Long-Term Survival of a Case with Brain and Lung Metastases from Resected Rectal Cancer by Gamma Knife Radiosurgery]."
##
##
## [[92]]
## [[92]]$text
## [1] "Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report"
##
##
## [[93]]
## [[93]]$text
## [1] "PURPOSE: To characterize the magnetic resonance (MR) imaging response of brain metastases after gamma knife stereotactic radiosurgery and determine whether imaging features and tumor response rates correlate with local tumor control and survival."
##
##
## [[94]]
## [[94]]$text
## [1] "As far as we know, this is the first study to analyse primary colorectal tumors and their related lung metastases and correlated KRAS mutational status based on both clinicopathological features and survival data."
##
##
## [[95]]
## [[95]]$text
## [1] "Long-Term Survival in a Patient with Multiple Brain Metastases from Small-Cell Lung Cancer Treated with Gamma Knife Radiosurgery on Four Occasions: A Case Report"
##
##
## [[96]]
## [[96]]$text
## [1] "We present a case report with a very long survival in which the role of repeated stereotactic radiosurgery (SRS) was investigated for a patient with a recurrent brain metastasis from non-small cell lung cancer in the same area."
##
##
## [[97]]
## [[97]]$text
## [1] "Long-Term Survival of a Patient with Brainstem and Recurrent Brain Metastasis from Stage IV Nonsmall Cell Lung Cancer Treated with Multiple Gamma Knife Radiosurgeries and Craniotomies: A Case Report and Review of the Literature"
##
##
## [[98]]
## [[98]]$text
## [1] "For the validation and test data, we used MRI data from an ongoing clinical study (NCT03458455) conducted at Hospital B. To be eligible for inclusion, patients had to receive stereotactic radiosurgery (SRS) for at least one brain metastasis measured at a minimum of 5 mm in one direction, be untreated or progressive after systemic or local therapy, have confirmed non-small-cell lung cancer (NSCLC) or malignant melanoma, be >=18 years of age; have an Eastern Cooperative Oncology Group performance status score <=1, and have a life expectancy >6 weeks."
##
##
## [[99]]
## [[99]]$text
## [1] "Clinical indicators included sex, date of diagnosis, age at the start of immunotherapy, TNM staging at diagnosis and immunotherapy initiation, pathological type of lung cancer, gene mutation status, molecular pathology of tumour, specimen source for genetic testing or PD-L1 detection, gene mutation and PD-L1 detection method, ECOG score, history of smoking at the start of diagnosis and immunotherapy, brain metastasis status at the time of diagnosis, time to starting treatment, treatment plan, time of progression, start date of immunotherapy, how many treatment lines had been completed prior to the initiation of immunotherapy, immunotherapy cycle, immunotherapy regimen, immune-related side effects, optimal efficacy, time of immunotherapy, and post-immune therapy."
##
##
## [[100]]
## [[100]]$text
## [1] "It would also be desirable to investigate whether these mutations contribute to cancer progression and survival, other than their relation with drug-response and -resistance, through follow-up studies examining the mutational status of INT subunits in lymph node and distant metastases tissues."
do.call("rbind",lapply(data, function (x) x[c("text")]))
## text
## [1,] "Survival but not brain metastasis response relates to lung cancer mutation status after radiosurger" [truncated]
## [2,] "Survival of non-small cell lung cancer patients with brain metastases treated with brain RT stratif" [truncated]
## [3,] "The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lu" [truncated]
## [4,] "The number of brain metastases predicts the survival of non-small cell lung cancer patients with EG" [truncated]
## [5,] "EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer."
## [6,] "This single institution retrospective study of patients with brain metastases from lung cancer who " [truncated]
## [7,] "Does lung cancer mutation status and targeted therapy predict for outcomes and local control in the" [truncated]
## [8,] "EGFR mutations are associated with favorable intracranial response and progression-free survival fo" [truncated]
## [9,] "Mutational status of lung cancer patients and survival outcomes for patients with limited brain met" [truncated]
## [10,] "In non-small cell lung cancer patients with brain metastases, combined Gamma Knife radiosurgery and" [truncated]
## [11,] "Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Smal" [truncated]
## [12,] "EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with" [truncated]
## [13,] "The Effect of Epidermal Growth Factor Receptor Mutation on Intracranial Progression-Free Survival o" [truncated]
## [14,] "Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer" [truncated]
## [15,] "Epidermal growth factor receptor mutations: association with favorable local tumor control followin" [truncated]
## [16,] "Purpose: Determine whether EGFR and KRAS mutations carry prognostic significance in non-small cell " [truncated]
## [17,] "In patients with lung adenocarcinoma and brain metastasis, the EGFR mutation status and concurrent " [truncated]
## [18,] "Tumor Histology Predicts Patterns of Failure and Survival in Patients With Brain Metastases From Lu" [truncated]
## [19,] "We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to d" [truncated]
## [20,] "We evaluated the effects of EGFR mutation status on responses and outcomes in non-small cell lung c" [truncated]
## [21,] "The median survival of brain metastases of lung cancer ranges from 2 months to 8 months based on ag" [truncated]
## [22,] "Mutation status and postresection survival of patients with non-small cell lung cancer brain metast" [truncated]
## [23,] "Out of radioresistant tumors, the median survival from the time of radiosurgery is shorter for brai" [truncated]
## [24,] "We proposed to identify the efficacy of an epidermal growth factor receptor (EGFR) tyrosine kinase " [truncated]
## [25,] "Comparative survival in patients with brain metastases from non-small-cell lung cancer treated befo" [truncated]
## [26,] "Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors " [truncated]
## [27,] "We prospectively addressed whether EGFR and KRAS mutations, EML4-ALK, ROS1 and RET rearrangements, " [truncated]
## [28,] "Survival in Patients with >=5 Brain Metastases From Non-Small Cell Lung Cancer Treated With Upfront" [truncated]
## [29,] "Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lun" [truncated]
## [30,] "Perilesional edema in brain metastasis from non-small cell lung cancer (NSCLC) as predictor of resp" [truncated]
## [31,] "BACKGROUND AND PURPOSE: To analyze outcomes of non-small cell lung cancer (NSCLC) patients with bra" [truncated]
## [32,] "Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small ce" [truncated]
## [33,] "Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metas" [truncated]
## [34,] "BACKGROUND: This study tested the hypothesis that time of day of treatment with stereotactic radios" [truncated]
## [35,] "A restrospective study of patients with brain metastases from non-small cell lung cancer (NSCLC) is" [truncated]
## [36,] "Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunothera" [truncated]
## [37,] "We compared the survival time between patients with multiple gamma knife radiosurgery (GKRS) and pa" [truncated]
## [38,] "Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung" [truncated]
## [39,] "Local recurrence and survival following stereotactic radiosurgery for brain metastases from small c" [truncated]
## [40,] "Overall and disease-free survival greater than 12 years in metastatic non-small cell lung cancer a" [truncated]
## [41,] "A phase 3 Radiation Therapy Oncology Group (RTOG) study subset analysis demonstrated improved overa" [truncated]
## [42,] "BACKGROUND: We investigated effects of genetic alterations in epidermal growth factor receptor (EGF" [truncated]
## [43,] "In non-small-cell lung cancer, TKIs have proven efficacy in improvement of progression-free surviva" [truncated]
## [44,] "The authors suggested that the lack of survival difference may be related to the high proportion (~" [truncated]
## [45,] "A review by Patil et al. on treatment of brain metastases shows that WBRT plus stereotactic radiosu" [truncated]
## [46,] "This study was conducted to determine prognostic factors for tumor response and patient survival af" [truncated]
## [47,] "[Two cases of lung cancer patients with postoperative brain metastases obtaining long-term survival" [truncated]
## [48,] "CONCLUSIONS: Younger patients with resected stage IIIA non-small cell lung cancer who have isolated" [truncated]
## [49,] "Patients with newly diagnosed EGFR-mutated lung cancer presenting to a neurosurgeon with a new diag" [truncated]
## [50,] "The purpose of this study was to examine the impact of epidermal growth factor receptor (EGFR) muta" [truncated]
## [51,] "OBJECT: The aim of this study was to evaluate the imaging response of brain metastases after radios" [truncated]
## [52,] "We report a case in which advanced lung cancer with mediastinal lymph node metastasis and recurrenc" [truncated]
## [53,] "Brain metastases constitute one of the most detrimental life-threatening condition in humans and ar" [truncated]
## [54,] "To determine the factors related to optimal treatment of brain metastasis from lung cancer by gamma" [truncated]
## [55,] "Multiple Gamma Knife Radiosurgery for Multiple Metachronous Brain Metastases Associated with Lung C" [truncated]
## [56,] "Thallium-201 SPECT in advanced non-small cell lung cancer: in relation with chemotherapeutic respon" [truncated]
## [57,] "We conclude that fractionated radiosurgery improves survival of patients with brain metastases from" [truncated]
## [58,] "Comment on "Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell" [truncated]
## [59,] "It is likely that patients with ALK+ or EGFR mutation+ lung cancer or breast cancer brain metastase" [truncated]
## [60,] "Studies suggest that stereotactic radiosurgery is preferable to whole-brain radiation therapy and t" [truncated]
## [61,] "Abbreviations: KPS, Karnofsky performance status; WBRT, whole-brain radiotherapy; SRS, stereotactic" [truncated]
## [62,] "Individualized early death and long-term survival prediction after stereotactic radiosurgery for br" [truncated]
## [63,] "This finding supports the hypothesis that the EGFR mutation in lung tumors could be related to the " [truncated]
## [64,] "PURPOSE: To evaluate the efficacy of gamma knife radiosurgery (GKRS) for the treatment of brain met" [truncated]
## [65,] "Female sex, younger age, higher Karnofsky performance status, controlled primary tumor, absence of " [truncated]
## [66,] "This study was aimed at optimizing the treatment of non-small-cell lung cancer (NSCLC) patients who" [truncated]
## [67,] "Early posttreatment assessment of MRI perfusion biomarkers can predict long-term response of lung c" [truncated]
## [68,] "[A case of long-term survival of postoperative brain metastasis of small cell lung cancer effective" [truncated]
## [69,] "Both previous cases had also advanced lung adenocarcinoma with brain metastasis, received therapy w" [truncated]
## [70,] "Multimodality MRI-based radiomics approach to predict the posttreatment response of lung cancer bra" [truncated]
## [71,] "Four investigated lung cancer patients undergoing stereotactic radiosurgery for brain metastases, w" [truncated]
## [72,] "We report two cases of lung cancer patients with postoperative solitary brain metastases obtaining " [truncated]
## [73,] "However, with the advent of newer systemic cancer therapies, survival is improving; this change man" [truncated]
## [74,] "Although emerging data from retrospective studies suggest that stereotactic radiosurgery is effecti" [truncated]
## [75,] "Pre-radiosurgery leucocyte ratios and modified glasgow prognostic score predict survival in non-sma" [truncated]
## [76,] "BACKGROUND: The aim of this study was to evaluate local control and survival rates after stereotact" [truncated]
## [77,] "[Advanced lung cancer with mediastinal lymph node metastasis and recurrence of brain metastasis com" [truncated]
## [78,] "Multivariate analysis showed that the presence of extracranial malignancy, performance status, mult" [truncated]
## [79,] "OBJECTIVES: To develop and validate a multimodality MRI-based radiomics approach to predicting the " [truncated]
## [80,] "OBJECTIVE: In the era in which more patients with greater numbers of brain metastases (BMs) are bei" [truncated]
## [81,] "Is survival or brain control different in selected patients with single brain metastasis (excluding" [truncated]
## [82,] "METHODS: In this retrospective analysis, outcomes of 50 patients who underwent linear accelerator-b" [truncated]
## [83,] "Therefore, we analyzed how combined local tumor treatment of brain metastases using robotic radiosu" [truncated]
## [84,] "PATIENTS AND METHODS: Patients with one to three brain metastases of solid tumors (small-cell lung " [truncated]
## [85,] "PURPOSE/OBJECTIVE(S): To compare the performance of five prognostic models [RTOG recursive partitio" [truncated]
## [86,] "Kaplan-Meier curves of (a) overall survival (OS) in EGFR-mutated non-small cell lung cancer patient" [truncated]
## [87,] "OBJECTIVE Following an initial response of brain metastases to Gamma Knife radiosurgery, regrowth o" [truncated]
## [88,] "61-year-old African American woman from Louisiana on investigative anti-PD-L1 and PARP-inhibitor th" [truncated]
## [89,] "To the best of our knowledge this is the first report on patients treated with linear accelerator-b" [truncated]
## [90,] "The primary lung cancer dataset (GSE3141) contained survival information and KRAS mutation status f" [truncated]
## [91,] "[Long-Term Survival of a Case with Brain and Lung Metastases from Resected Rectal Cancer by Gamma K" [truncated]
## [92,] "Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain met" [truncated]
## [93,] "PURPOSE: To characterize the magnetic resonance (MR) imaging response of brain metastases after gam" [truncated]
## [94,] "As far as we know, this is the first study to analyse primary colorectal tumors and their related l" [truncated]
## [95,] "Long-Term Survival in a Patient with Multiple Brain Metastases from Small-Cell Lung Cancer Treated " [truncated]
## [96,] "We present a case report with a very long survival in which the role of repeated stereotactic radio" [truncated]
## [97,] "Long-Term Survival of a Patient with Brainstem and Recurrent Brain Metastasis from Stage IV Nonsmal" [truncated]
## [98,] "For the validation and test data, we used MRI data from an ongoing clinical study (NCT03458455) con" [truncated]
## [99,] "Clinical indicators included sex, date of diagnosis, age at the start of immunotherapy, TNM staging" [truncated]
## [100,] "It would also be desirable to investigate whether these mutations contribute to cancer progression " [truncated]
############ref https://www.ncbi.nlm.nih.gov/research/litsense/?view=tutorial#tut-api